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Abstract
We present two patients with three-vessel disease and severely depressed left ventricular (LV) systolic function where viability
analysis by cardiac magnetic resonance imaging demonstrated areas of near-transmural sub-endocardial ﬁbrosis and hence
little chance of regaining systolic function as judged by conventional analysis from radial function. Despite the pessimistic
cardiac magnetic resonance imaging analysis, however, the patients underwent full revascularization and regained impressive
increases in LV systolic function mainly based on improved longitudinal systolic segment function. The cases highlight that sub-
epicardial, longitudinally oriented myocytes can contribute to overall LV systolic function and suggest taking their ‘piston-
function’ into consideration when analysing viability.
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Introduction
Cardiac magnetic resonance imaging (CMR) with late
gadolinium enhancement (LGE) has become a preferred
technique for determination of ﬁbrosis and hence viability in
ischaemic cardiomyopathy. Analysis is based on studies
demonstrating improvement in radial contractility
(myocardial thickening) following revascularization in hypo-
or akinetic segments without substantial transmural
ﬁbrosis.1,2 With >75% transmural ﬁbrosis, minimal
improvement in radial contractility can be expected. However,
analysis based on potential improvements in myocardial
thickening mainly takes into account the function of mid-
myocardial ﬁbres and little account of the function of sub-
epicardial ﬁbres that (like the sub-endocardial) are involved
in longitudinal function primarily.3 In patients with severe
ischaemic cardiomyopathy, we extend viability analysis to
potential gains in not only radial but also in longitudinal left
ventricular (LV) systolic function. As a demonstration of this
way of thinking, we here present two patients with three-
vessel coronary artery disease and severely depressed systolic
function in whom revascularization was decided on despite
>75% transmural ﬁbrosis on LGE CMR because alternative
options were considered too difﬁcult.
Case reports
A 65-year-old woman presented with severe shortness of
breath [New York Heart Association (NYHA) Class IV] and signs
of a previous inferior wall infarction with pathologic Q-waves
in II, III, and aVF on electrocardiogram. Coronary angiography
proved severe three-vessel coronary artery disease, and
following initial stabilization, the patient was initiated on
guideline recommended heart failure medication. Four weeks
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following initial admission, CMR showed a severely dilated LV
[LV end-diastolic volume (LVEDV) of 265 mL (133 mL/m2)], an
LVEF of 14%, and widespread areas of near-transmural ﬁbrosis
in the left circumﬂex artery (LCX) and right coronary artery
territories, but little ﬁbrosis in the left anterior descending
artery territory (Figure 1A; Movies S1 and S2). Heart
transplantation was decided against, and percutaneous
coronary intervention (PCI) of all three vessels was performed
with a total of seven drug eluting stents. Three months after
the PCI and on guideline recommended target dose of
spironolactone, metoprolol, and maximum tolerated dose of
losartan, a follow-up CMR showed that the LVEDV had
decreased to 234 mL and LVEF improved to 37% (Movies S3
and S4). The LGE imaging demonstrated no procedural
infarction. Radial function improved very little, including the
inferior and lateral wall with up to >75% ﬁbrosis (Figure 3).
Figure 1 (A) Late gadolinium enhancement short axis images at a basal (upper left), midventricular (upper right), and apical (lower left) level and four-
chamber image with widespread areas of near-transmural ﬁbrosis in LCX and right coronary artery territories but little ﬁbrosis in the left anterior
descending artery territory. (B) Pre-percutaneous coronary intervention (PCI) two-chamber (upper panels) and four-chamber (lower panels) images
with end-diastolic (left) and end-systolic (right) measurements of AV-plane displacement. (C) Post-PCI two-chamber (upper panels) and four-chamber
(lower panels) images with end-diastolic (left) and end-systolic (right) measurements of AV-plane displacement, which improved to >9 mm in all
segments.
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However, atrioventricular (AV)-plane displacement improved
from <3 to 9–11 mm in all segments, including the inferior
wall where only a little sub-epicardial viable tissue was found
(Figure 1B–C). Six months after her revascularization, the
patient was symptom-free (NYHA Class I).
A 47-year-old previously healthy man presented with
gradually increasing shortness of breath over the previous
3 months, on admission corresponding to NYHA Class IV.
Initial work-up with electrocardiogram and troponins found
no acute coronary syndrome or pulmonary embolism but
signs of a previous lateral myocardial infarction.
Echocardiography showed severely depressed systolic
function. The patient was put on maximum tolerated doses
of guideline heart failure medication, including ramipril,
carvedilol, and spironolactone. Six weeks following initial
admission, CMR demonstrated a severely dilated LV [LVEDV
of 336 mL (149 mL/m2)], an LVEF of 15% and 50%
transmural ﬁbrosis in the anterolateral wall at a basal and
Figure 2 (A). Late gadolinium enhancement short axis images at a basal (upper left), midventricular (upper right), and apical (lower left) level and four-
chamber image with 50% transmural ﬁbrosis in the anterolateral wall at a basal and midventricular level and up to 75% transmural ﬁbrosis in the whole
circumference at an apical level. (B) Pre-CABG two-chamber (upper panels) and four-chamber (lower panels) images with end-diastolic (left) and end-
systolic (right) measurements of AV-plane displacement. (C) Post-CABG two-chamber (upper panels) and four-chamber (lower panels) images with
end-diastolic (left) and end-systolic (right) measurements of AV-plane displacement, which improved from 1 mm in all areas to 6, 5, 5, and 7 mm
in the two-plane (anterior and inferior) and four-plane (medial and lateral) views, respectively.
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mid-ventricular level, and >75% transmural ﬁbrosis in the
whole circumference at an apical level (Figure 2A; Movies
S5 and S6). Positron Emission Tomography (PET) imaging
did not suggest signiﬁcant viability, but based on LGE CMR,
it was decided to pursue coronary artery bypass grafting
(CABG) and following grafting of all territories, LV function
improved. The patient recovered to NYHA Class I, the LVEDV
decreased to 284 mL, and the LVEF improved to 28% (Movies
S7 and S8). There was no additional LGE, documenting no
CABG-related infarction. Radial function improved only slightly
in the basal anterior wall (with approximately 50% ﬁbrosis) and
not at all in themid-ventricular and apical segments with>75%
ﬁbrosis (Figure 3). Thus, the improvement of LV function was
largely due to improvements in longitudinal motion. The AV-
plane displacement improved from 1, 1, 1, and 1 mm to 6, 5,
5, and 7 mm in the two-plane (anterior and inferior) and
four-plane (medial and lateral) views, respectively (Figure 2B–
C). Longitudinal shortening of the mid-ventricular and apical
part of the LV (with up to 75% transmural ﬁbrosis) improved
from 1, 0, and 0 mm to 11, 3 and 7 mm, respectively
(determined corresponding to ﬁxed anatomical points
including insertion of papillary muscle and septal origin of the
moderator band) (Figure 2B–C).
Discussion
Mid-myocardial ﬁbres have a predominantly circumferential
orientation, and hence, shortening of these ﬁbres will mainly
contribute to radial contractility. Sub-endocardial and sub-
epicardial ﬁbres have longitudinal orientations with the sub-
endocardial describing a right-handed helix (as seen from
the apex) and the sub-epicardial describing a left-handed.3
Based on this anatomical knowledge, it is understandable
that >75% ﬁbrosis will seriously limit radial contractility,
whereas <25% ﬁbrosis will not. If only the sub-epicardial
layer is spared, substantial improvements in radial
contractility cannot be expected with revascularization, but
in our patients, revascularization of this viable sub-epicardial
layer contributed to a signiﬁcant improvement in longitudinal
LV shortening. In these two cases, this improvement in
longitudinal shortening helped improve overall systolic
function as also reﬂected in ejection fractions. If ﬁndings
from the STICH trial4 (median LVEF 28% and 27% in the
medically treated group and CABG group, respectively) had
been extrapolated to our patients, they may not have been
revascularized. Although we cannot tell what would have
happened to our patients if not revascularized but
conservatively treated with heart failure medication, we
believe that the impressive increases in LVEF with
concomitant improvements in NYHA class from IV to I were
probably largely due to the revascularization in itself. Beta-
blocker therapy can contribute to an increase in LV
function,5,6 but the effect of Angiotensin-converting enzyme
Figure 3 Segmental (American Heart Association 16-segment model)
late gadolinium enhancement (%) (Rows 1 and 4); mean diastolic
wall thickness (mm) (Rows 2 and 5); and mean wall thickening (%)
(Rows 3 and 6) before (left panels) and after revascularization (right
panels).
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inhibitors and mineralocorticoid receptor antagonists on
LVEF is less well established. Some echocardiographic studies
have found a minor increase in LVEF with the latter,7,8
although not sufﬁcient to explain the overall beneﬁcial effect
of treatment. These case reports may serve as an inspiration
that in such patients, even in areas with only little sub-
epicardial viable myocardium left, one should not completely
dismiss such segments but consider applying analysis based
on the kind of systolic function predominantly performed
by these ﬁbres, that is, the longitudinal shortening and hence
‘piston-function’ of the left ventricle. The cases may also
serve as an inspiration for analysis with gadolinium analysis





Additional Supporting Information may be found online in
the supporting information tab for this article.
Movie S1 Four-chamber cine loop with a severely dilated left
ventricle (LV) with depressed systolic function; LV ejection
fraction 14%.
Movie S2 Two-chamber cine loop with a severely dilated left
ventricle (LV) with depressed systolic function; LV ejection
fraction 14%.
Movie S3 Post-percutaneous coronary intervention (PCI)
four-chamber cine loop with improved LV systolic function
(LV ejection fraction 37%) and markedly increased AV-plane
displacement.
Movie S4 Post-percutaneous coronary intervention (PCI) two-
chamber (D) cine loop with improved LV systolic function (LV
ejection fraction 37%) and markedly increased AV-plane
displacement.
Movie S5 Four-chamber cine loop with a severely dilated left
ventricle (LV) with depressed systolic function; LV ejection
fraction: 15%.
Movie S6 Two-chamber cine loop with a severely dilated left
ventricle (LV) with depressed systolic function; LV ejection
fraction: 15%.
Movie S7 Post-CABG four-chamber cine loop with improved
LV systolic function (LV ejection fraction 28%) and markedly
increased AV-plane displacement.
Movie S8 Post-CABG two-chambe cine loop with improved
LV systolic function (LV ejection fraction 28%) and markedly
increased AV-plane displacement.
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